Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

Amgen Inc. urged a federal judge to overturn a jury’s $50.3 million verdict for its leukemia drug Blincyto’s infringement of ...

Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...